respiratory exacerbations by 22 to 34% and an increase in the well-being of the patient were observed. With placebo, neither increase in lung function nor decrease in exacerbations was observed. The long-term inhalation of rhDNase I was found to improve, or at least maintain, lung function in patients with advanced  and mild lung disease[77-79]. This is a striking and important observation, as the former are at a greater risk of losing lung function , while the latter can hardly improve their lung functions as the baseline values are close to 100% of the predicted values . Many other nonrandomized placebo-controlled studies have revealed similar data [80-83]. Additionally, Suri, et al.  showed in a randomized trial that inhalation of rhDNase I on alternate days is as effective as daily inhalation. Recently, a long-term trial over a period of 3 years revealed that inhalation of rhDNase I also had a positive impact on airway inflammation in CF patients .
In 1998, inhalation of rhDNase I was demonstrated to be safe in children younger than five years. This led to the approval of rhDNase I for the treatment of CF patients under the age of 5 . Later on, studies showed that, over a long term, younger patients appear to benefit more from rhDNase I therapy than older, and often more sickly patients [68,78].
Was this article helpful?
If you suffer with asthma, you will no doubt be familiar with the uncomfortable sensations as your bronchial tubes begin to narrow and your muscles around them start to tighten. A sticky mucus known as phlegm begins to produce and increase within your bronchial tubes and you begin to wheeze, cough and struggle to breathe.